Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Next Previous
Search
Trial Profile

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilvegostomig (Primary) ; Volrustomig (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms GEMINI-Gastric
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 13 Feb 2025 Planned End Date changed from 31 Mar 2026 to 28 Jan 2027.
    • 13 Feb 2025 Planned primary completion date changed from 30 Sep 2025 to 30 Jan 2026.
    • 03 Sep 2024 According to an AstraZeneca media release, at ESMO, a poster presentation sharing the first report of overall response rate and safety data from Substudy 2 of the GEMINI-Gastric Phase II trial, testing rilvegostomig (AZD2936) plus chemotherapy as a 1st-line treatment in patients with HER2-negative, locally advanced unresectable or metastatic GEJ cancers.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top